Chronic Rhinosinusitis

The FDA approved Celltrion’s omalizumab biosimilar, Omlyclo, for the treatment of multiple conditions including asthma and food allergy, according to an agency press release.

SAN DIEGO — Among patients with chronic rhinosinusitis, higher IL-6 and IL-8 levels had links to decreases in several cognitive function domains including episodic memory and attention/processing speed, according to a presentation here.

Patients with severe chronic rhinosinusitis with nasal polyps experienced significant improvements in their symptoms with tezepelumab-ekko compared with placebo, according to a press release from Amgen and AstraZeneca.

BOSTON — Patients with chronic rhinosinusitis with nasal polyps showed low biologics use and high discontinuation rates, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

A retrospective chart review revealed a 50% increase in outpatient pediatric psychology referrals from the Food Allergy Treatment Center between 2013 and 2023.

BOSTON — Patients aged 65 years and older on dupilumab for asthma and chronic rhinosinusitis experienced greater risks for adverse events than younger patients, according to a poster presented at the CHEST Annual Meeting.

Regeneron Pharmaceuticals Inc. and Sanofi announced the FDA approval of dupilumab for adolescents aged 12 to 17 years with chronic rhinosinusitis with nasal polyps.

People born in fall and winter months in Finland were more likely to develop asthma and allergic rhinitis vs. those born in spring and summer, according to a study published in Allergy.

Dupilumab showed continuous efficacy and safety in the long-term treatment of atopic dermatitis, according to a study.

Researchers traced childhood illnesses like asthma, frequent head colds and tonsilitis to the development of chronic rhinosinusitis in middle age in a population-based study.